Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

CytomX Therapeutics, Inc. CTMX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
69/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.60
+155.5%

CytomX Therapeutics, Inc. (CTMX) is a Biotechnology company in the Healthcare sector, currently trading at $4.54. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is CTMX = $12 (+155.5% upside).

Valuation: CTMX trades at a trailing Price-to-Earnings (P/E) of -41.4 (S&P 500 average ~25).

Financials: revenue is $76M, +27.3%/yr average growth. Net income is $17M (loss), growing at +1881.9%/yr. Net profit margin is -22.8% (negative). Gross margin is 100% (+11 pp trend).

Balance sheet: total debt is $4M against $99M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 3.09 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $152M.

Analyst outlook: 17 / 21 analysts rate CTMX as buy (81%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 56/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$11.60
▲ 155.51% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for CytomX Therapeutics, Inc., the average price target is $11.60, with a high forecast of $16.00, and a low forecast of $10.00.
Highest Price Target
$16.00
Average Price Target
$11.60
Lowest Price Target
$10.00

CTMX SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 56/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CTMX

✓
VALUE Pass
100/100
CTMX trades at a trailing Price-to-Earnings (P/E) of -41.4 (S&P 500 average ~25). Forward PEG -4.08 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.42. Analyst consensus target is $12, implying +164.3% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
CTMX: +27.3%/yr revenue is, +1881.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
CTMX: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet CTMX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 3.09 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
56/100
CTMX: Gross margin is 100% (+11 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 56/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 17 / 21 analysts rate CTMX as buy (81%). Analyst consensus target is $12 (+164.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CTMX: Net profit margin is -22.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.4-8.21
Volume6.56M
Avg Volume (30D)6.98M
Market Cap$772.94M
Beta (1Y)2.48
Share Statistics
EPS (TTM)-0.15
Shares Outstanding$137.94M
IPO Date2015-10-08
Employees119
CEOSean A. McCarthy
Financial Highlights & Ratios
Revenue (TTM)$76.2M
Gross Profit$76.2M
EBITDA$-18.19M
Net Income$-17.37M
Operating Income$-19.56M
Total Cash$137.05M
Total Debt$4.24M
Net Debt$-8.43M
Total Assets$151.57M
Price / Earnings (P/E)-30.3
Price / Sales (P/S)10.14
Analyst Forecast
1Y Price Target$10.00
Target High$16.00
Target Low$10.00
Upside+120.3%
Rating ConsensusBuy
Analysts Covering21
Buy 81% Hold 19% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS23284F1057

Price Chart

Track all markets on TradingView
CTMX
CytomX Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.40 52WK RANGE 8.21

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message